Download Company Overview

Company Overview
A legacy of leadership
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company specializing in
pharmaceuticals. Its corporate headquarters are in Israel where the Company is the
uncontested leader in the production, sale and distribution of pharmaceutical products. Teva
has major manufacturing and marketing facilities in Israel, North America and Europe.
With more than a century of experience in the healthcare industry, the Company enjoys a
firmly established international presence, operating through a carefully tailored network of
worldwide subsidiaries. In 2003, Teva posted an impressive $3.276 billion in sales generating
net income of $617.8 million. With approximately 13,000 employees and multiple international
production facilities at its disposal, the Company is poised to cultivate and increase its
strategic role as a major leader in the worldwide pharmaceutical market.
Fully-integrated pharmaceuticals
Teva's scope of activity extends to many facets of the industry, with a primary focus on the
manufacturing and marketing of products in the following categories:

Human pharmaceuticals - Teva produces generic drugs in all major therapeutics
and steriles in a variety of dosage forms, from tablets and capsules to ointments,
creams and liquids. In addition, Teva manufactures innovative drugs in niche markets
where it has a relative advantage in research and development.
 Active Pharmaceutical Ingredients (API) - competitively distributes its API to
manufacturers worldwide as well as supports its own pharmaceutical production.
These activities, which comprise the core businesses of the company, account for 90% of
Teva's total sales.
Generic pharmaceuticals: A comprehensive portfolio
Teva believes that its product diversity will continue to be of strategic significance, paralleling
the needs of an emerging and dynamically evolving generic industry deeply affected by trends
of consolidation among managed care providers, large pharmacy chains, wholesaling
organizations and other buyers groups. Teva Pharmaceuticals USA, the company's whollyowned American subsidiary, is the jewel in the crown of Teva's international efforts in the
generic pharmaceuticals arena and one of the most successful manufacturers and distributors
of generic drugs in the U.S.
Teva USA is an integral part of Teva North America which encompasses USA and Canada.
The company's impressive line offers the discerning American consumer an extensive
portfolio of competitively priced products in diverse dosage forms. Its vast experience with
compliance to the stringent requirements of the U.S. Food and Drug Administration and
proven manufacturing experience following FDA standards, are indicators of Teva's
significant advantages. The company pipeline is one of the broadest in the industry.
Teva's forays into the European market include successfully established subsidiaries in The
U.K., Hungary, and The Netherlands, each attuned to the specific needs of its local consumer
base. Following the purchase of the Dutch industry heavyweight Pharmachemie B.V., Teva
has gained the largest share in one of Europe's most generically-active markets. Future
strategic acquisitions and alliances such as these will help propel Teva to the pinnacle of the
European generic scene.
R&D: Innovation at the core
Teva's innovative products are developed for specialized markets with the current focus on
neurological disorders and auto-immune diseases. Maintaining ongoing collaborative efforts
with Israel's major universities, hospitals and research institutes is an important core element
of Teva's approach to innovative Research and Development. Currently, Teva has novel
treatments for MS, Parkinson's Disease (PD), Alzheimer's disease (AD), epilepsy and other
CNS indications as well as Systemic Lupus Erythematosus in clinical research phases.
Copaxone
®: A breakthrough treatment offers hope
Copaxone®, a proprietary branded product used for the treatment of multiple sclerosis,
was developed by Teva's R&D team and marks an important milestone in the company's
development as it expands its activities to include innovative products. This exclusive
drug is currently marketed and sold in 43 countries including the U.S., Canada, The
U.K., Germany, Argentina, Israel and Australia. This is the first nonsteroidal, noninterferon agent for treating patients with relapsing-remitting MS - a major breakthrough
in the treatment of this devastating disease.
API: Supplying the world with healthy ingredients
In addition to the production and sale of finished pharmaceutical products, Teva is a large
manufacturer and provider of Active Pharmaceutical Ingredients, the vital raw materials of the
drug manufacturing industry. In addition to supplying a major share of Teva's own needs, the
API division is an active competitor in world markets, investing both in the development of
new products and manufacturing processes and in the upgrading of production facilities. It
also provides an essential link in Teva's strategic marketing chain. The division often
spearheads the company's entry into new drug markets, providing a cost effective source of
materials with which to commence local manufacturing and establishing viable distribution
channels.
A vision of values
Teva's far-reaching strategic vision is rooted in staying consistently attuned to the dynamic
requirements of a diverse, international clientele that includes insurers, physicians, patients
and pharmaceutical outlets. In the ongoing effort to make the world a healthier place, Teva
values its worldwide staff as an irreplaceable resource that deserves to be nurtured in a
carefully cultivated global organizational culture. Teva will focus its future efforts on an
expanded international presence while maintaining sensitivity to the localized needs of
regional markets, and continue to supply products of uncompromised quality in all areas of its
multi-faceted operation.
The History of Teva
1901: Laying the foundations
Teva was founded in Jerusalem in 1901 as a small wholesale drug business in Jerusalem
that distributed imported medicines loaded onto the backs of camels and donkeys, to
customers throughout the land. The company was called Salomon, Levin and Elstein Ltd.,
after its founders. From that day until the present this name has served as the pharmaceutical
marketing arm of Teva in Israel.
1930s: Establishing the Israeli pharmaceutical industry towards the founding of the
State of Israel
Following the immigration of many pharmaceutical professionals from Central Europe, local
pharmaceutical plats were founded. Among the many young European immigrants to
Palestine were a number of scientists, chemists and technicians, who began building medical
and pharmaceutical businesses including Teva, Zori and Assia which later on became part of
Teva. The new plants operated on a small scale and were faced with numerous difficulties,
such as competing with imports, receiving supplies and gaining approval from health and
medical authorities.
1940s & 50s: Industry grows with mass immigration
The pharmaceutical industry gained momentum during the Second World War, when these
small plants became the sole source of drug supply for the local market, neighboring
countries and the armies stationed in the vicinity. Mass immigration following the founding of
the state of Israel in 1948 resulted in rapid growth of the local drug market. While drug imports
were gradually resumed, at the same
time local manufacturers began to seek export markets.
The 50s saw the start of the public financial market in Israel. In 1951 Teva, as one of the first
industrial companies, raised capital through an initial public offering on the Tel Aviv Stock
Exchange.
1960s & 70s: Consolidating a fragmented industry
With the aim of greater efficiency and concentration in the areas of research and
development, marketing and exports, the larger firms began to acquire smaller
pharmaceutical companies. In 1964, Assia and Zori merged and later acquired a controlling
interest in Teva. In 1976 the three firms merged formally into one company - Teva
Pharmaceutical Industries Ltd., Israel's largest healthcare company, transforming Teva into a
group of companies involved in a variety of fields. Assia's CEO Eli Hurvitz became Teva's
CEO and President, a position he fulfilled until 2002. Today he serves as Teva's Chairman of
the Board.
Through a series of acquisitions and joint ventures, these decades saw the beginning of
exports and the opening of many new markets for Teva.
1980s: Establishing leadership
In 1980, Teva acquired the second largest Israeli drug manufacturer Ikapharm (later dissolved
in 1982 and merged into Teva) together with Plantex - an API manufacturer. This acquisition
enabled Teva to separate penicillin production and non-penicillin drugs, an essential
requirement of international health authorities, paving the way for Teva's entry to the US
market. In 1982 Teva was granted FDA approval for its Kfar Saba (Ikapharm) manufacturing
plant. At the same time, Teva commenced trading its American Depository Receipts (ADRs)
on the NASDAQ, over the counter market in the USA.
in 1984 Teva acquired a 50% interest in Migada Ltd., a manufacturer of disposable medical
equipment. Through this acquisition Teva significantly expanded its activity in the field of
medical devices, a field with high growth potential.
In 1985, a joint company was set up between Teva and the US conglomerate W.R. Grace
which in 1986 acquired Lemmon, a small generic manufacturer in Pennsylvania. These steps
enabled Teva to further penetrate the American market.
In 1988 Teva bought Abic the second largest Israeli pharmaceutical company.
During this decade Teva became Israel's largest and most successful pharmaceutical
company and one of the flagships in the Israeli industry. With the corporate headquarters
located in Israel, the company is the leader in production, sales and distribution of
pharmaceutical products.
1990s: Creating worldwide presence
Through the 90s Teva continued to expand and became a major player in the global generic
market by adopting an aggressive M&A strategy in the in the US.
This decade commenced with the buyout of W.R. Grace's interest in the joint venture
following by the acquistion of Biocraft.
Later on in the decade this strategy was also implemented in Europe with the acquisition
of GRY-Pharm, APS/Berk, Biogal, Pharmachemie and others.
This decade also saw the fruits of 10 years intensive and innovative R&D activities with
the launch of Copaxone®, a treatment for multiple sclerosis. Copaxone® is currently
marketed in the US and Canada by Teva Neuroscience, after gaining full ownership of
Teva-Marion Partners in 2001.
21st Century: Planning ahead
In the year 2000, Teva's acquisition of Novopharm in Canada, together with its Hungarian
subsidiary, Human Ltd, led Teva to become the largest generic pharmaceutical company in
North America.
Teva continued to expand its presence worldwide with the acquisition in 2002 of Teva
(previously Bayer) Classics in France, which included the Teva Sante manufacturing plant in
Sens. And finally the acquisition of the Honeywell Fine Pharmaceutical Chemi cal plants in
northern Italy, renamed Teva PFC, has added to the range of Teva's API products
manufactured worldwide.
On January 22, 2004, Sicor became a wholly owned subsidiary of Teva. This acquisition
brings together two premier generic pharmaceutical companies, combining Teva’s successful
oral dose generic drugs franchise with Sicor’s leading generic injectable business. In addition,
both the Active Pharmaceutical Ingredients (API) businesses and Sicor’s biogenerics
capabilities will enhance and expand the combined company’s product offerings.
With over a century of experience in the health care industry the company enjoys firmly
established international presence, operating through a strategic tailored network of
worldwide subsidiaries. Teva has major manufacturing and marketing facilities i n Israel,
Europe and the US.
Today, Teva is among the top 25 pharmaceutical companies in the world and one of the
largest generic pharmaceutical companies in the world.
Teva is among the most traded shares on the Tel Aviv Stock Exchange and among the most
widely held Israeli shares on NASDAQ. It is also traded on Seaq International in London and
the Frankfurt Stock Exchange.
Subsidiaries and Associated Companies
Company
Telephone
Fax
Israel
Teva Pharma Israel
Pharmaceutical and medical products
P.O.B. 8077 Kiryat Nordau, Netanya, Israel
++972-9-8639777
++972-9-8653764
Salomon, Levin and Elstein Ltd.
Pharmaceuticals distributor
P.O.B. 8077 Kiryat Nordau, Netanya, Israel
++972 9 8927878
++972 9 8854766
Abic Veterinary
Veterinary products
P.O.B. 489, Beit Shemesh 99100, Israel
++972-2-9906906
++972-2-9906900
North America
Teva Pharmaceuticals North America
Pharmaceutical products
1090 Horsham Rd. P.O.B. 1090
North Wales, PA 19454
U.S.A
++1-215-5913000
++1-215-5918600
Novopharm
Pharmaceutical products
30 Novopharm Court
Toronto, Ontario M1B 2K9
Canada
++1-416-2918876
++1-416-2915555
Plantex USA, Inc.
Active Pharmaceutical Ingredients
482 Hudson Terrace Englewood Cliffs
NJ 07632
U.S.A
++1-201-5671010
++1-201-5677994
Sicor, Inc.
++1-800-729-9991 (Toll
++1-949-855-8210
Sicor Headquarters
19 Hughes
Irvine, CA 92618
U.S.A
Teva Neuroscience
Innovative pharmaceuticals
901 E. 104th Street, Suite 900,
Kansas City, MO 64131
U.S.A
Free)
++1-816-5085000
++1-816-5085016
Europe
Teva Pharmaceuticals Europe B.V.
European Headquarters
Industrieweg 23 P.0.B. 206,
3640 AE Mijdrecht
The Netherlands
++31-29-7290200
++31-29-7290299
Pharmachemie B.V. and its related
companies
Pharmaceutical products
Swensweg 5, P.0.B. 552,
2003 RN Haarlem
The Netherlands
++31-23-5147147
++31-23-5312879
Teva Pharma UK
Pharmaceutical products
Barclays House1 Gatehouse Way
Aylesbury Bucks HP19 8DB
Great Britain
++44-129-6719768
++44-129-6719769
Aps/Berk Ltd.
Pharmaceutical products
Leeds Business Park, 18 Bruntcliffe Way,
Morley, Leeds LS27 OJG
Great Britain
++44-113-2380099
++44-113-2381800
Biogal Pharmaceutical Works
Active Pharmaceutical Ingredients &
Pharmaceutical products
13, Pallagi St. H-4042 Debrecen
Hungary
++36-52-515100
++36-52-311633
Biogal-Teva Pharma Ltd.
Pharmaceutical products
Robert Karoly krt. 66 H-1134 Budapest
Hungary
++36-1-2886400
++36-1-2886410
Human Pharmaceutical Manufacturing
Co.Ltd.
Pharmaceutical products
Tancsics Mihaly Ut 82 2100 Godollo
Hungary
++36-28-532100
++36-28-420177
Teva Classics France
Pharmaceutical products
Immeuble le Palatin 1
1, cours du Triangle de l'Arche
92936 Puteaux (Paris)
La Defense Cedex 12
France
++33-1-55-91-7800
++33-1-55-91-7941
C.E.R.A.
Centre for European Regulatory Affairs
87, route du Gué des Grues 28260 Sorel
++33-2-3741-6800
++33-2-3743-5187
Moussel
France
Teva Sante
Pharmaceutical products
Rue Bellocier - BP 713
89107 Sens Cedex
France
++33-3-86-95-71-00
++33-3-86-64-1781
Teva Pharma, GRY-Pharma, Teva Generics
Pharmaceutical products
++49-6105-976760
Kandelstrasse 10 D-79199 Kirchzarten
++49-7661-984501
Germany
++49-6105-976761
++49-7661-984569
Teva Pharma Italia S.r.l.
Pharmaceutical products
Via Giulio Richard, 7 (floor 8) 20143 Milano
Italy
++ 39-02-8917981
++ 39-02-89179825
++39-031-8721
++39-031-872-353
++39-02-9659071
++39-02-9657495
Teva Pharma Belgie
Pharmaceutical products
Laarstraat 10 Antwerpen-Wilrijk
Belgium
++32-3-8207373
++32-3-8207371
Teva CR
Representative office for the Czech Republic
Andryskova 21, Brno 63600
Czech Republic
++420-5-48226521
++420-5-48226525
Teva Slovakia, s.r.o.
Kosatcova 26
841 07, Bratislava
Slovakia
+421 2 6453 6530
Teva Generics Sweden AB
Sundstorget 2, Helsingborg
P.O. Box 1070, 251 10 Helsingborg
Sweden
++46-42-121100
++46-42-121108
Teva API Spain
Rambla Catalunya, 66
08008 Barcelona
Spain
++34-63-9313236
++34-93-2160314
Teva Pharmaceutical Fine Chemicals
S.r.l.(Teva PFC)
23892 Bulciago (LC)
Strada Statale Briantea 83
and
21042 Caronno Pertusella (VA)
Via Fermi Enrico 520
Italy
International Pharmaceutical Division
Teva-Tuteur S.A.C.I.F.A.
Pharmaceutical products
Encarnación Ezcurra 365,
C1107CLA Puerto Madero,
Buenos Aires,
Argentina
++54-11-57872222
++54-11-57872027
Teva Curacao
Latin America Representative office
Schotegatweg Oost 29 D, Curacao
Netherlands Antilles
++5999-7366066
++5999-7367066
Teva Pharmaceutical (Pty) Ltd., South
Africa
Representative office for South Africa
++27-11-4742555
26 Blumberg St.Industria 2093 Johannesberg
South Africa
++27-11-4743594
Assia Pharmaceuticals Ltd.
Representative office for Kenya
Funzi Road P.O.B. 30620 Nairobi
Kenya
++254-2-537622
++254-2-537628
Teva Singapore
Representative office for the Far East region
#10-06 the Concourse
300 Beach Road
Singapore 199555
++65-6392-2449
++65-6392-2729
Teva Moscow
Representative office for Russia
++7-095-7211739
Nauchny proezd 8 office 226 Moscow 117246
Russia
Teva Belarus
Representative office for Belarus
Pulichov St. 5/25 Minsk
Belarus
++375-172-363650
++375-172-100742
Teva Ukraine
Representative office for Ukraine
Krasnotkatskaya St. 29/24 Kiev 253094
The Ukraine
++38-04-2777757
++38-04-2777757
SICOR Inc. is a vertically integrated, multinational pharmaceutical company that
focuses on finished dosage injectable pharmaceuticals, active pharmaceutical
ingredients, or APIs, and biopharmaceuticals. Using internal research and
development capabilities, together with operational flexibility and manufacturing
and regulatory expertise, SICOR is able to take a wide variety of products from
the laboratory to the worldwide market. SICOR's goal is to become a leading
multinational developer, manufacturer and marketer of injectable pharmaceutical
and biopharmaceutical products.
Most recently, Teva Pharmaceutical Industries Ltd announced that they have
completed their acquisition of Sicor. For more information, please access Teva's
website.
Teva Neuroscience, Inc., formerly Teva Marion Partners, markets COPAXONE®
(glatiramer acetate injection).
Research shows COPAXONE® is well tolerated and effective in reducing the frequency
of relapses caused by RRMS. COPAXONE® is believed to cause a shift in the T-cell
population from inflammatory (TH1) to anti-inflammatory (TH2) at the site of CNS
inflammation.
Teva Neuroscience offers a total approach to disease management and has established
several innovative and effective patient education and advocacy programs. These
include MSWatch® (www.mswatch.com) and Shared Solutions® (1-800-887-8100), a
premier support program for MS patients.
Teva Neuroscience and Teva Pharmaceuticals committed $200 million to neurological
research through 2003. Additionally, Teva Neuroscience looks to branch out into other
areas of neurology.
Teva Neuroscience has forged strong partnerships with neurologists and professional
organizations also dedicated to supporting and improving the lives of people with MS,
including the American Academy of Neurology (AAN), the International Organization of
MS Nurses (IOMSN), Women Neurologists' MS Initiative (WNMSI), and the National MS
Society.
Teva Neuroscience is a subsidiary of Teva Pharmaceutical Industries Ltd.
COPAXONE® (glatiramer acetate injection) is indicated for the reduction of relapses in
relapsing-remitting multiple sclerosis.
The most common side effects of COPAXONE® are redness, pain, swelling, itching, or a
lump at the site of injection, flushing, chest pain, weakness, infection, pain, nausea, joint
pain, anxiety, and muscle stiffness. These reactions are usually mild and seldom require
professional treatment. Be sure to tell your doctor about any side effects.
Some patients report a short-term reaction right after injecting COPAXONE®. This
reaction can involve flushing (feeling of warmth and/or redness), chest tightness or pain
with heart palpitations, anxiety, and trouble breathing. These symptoms generally appear
within minutes of an injection, last about 15 minutes, and go away by themselves without
further problems